Abstract
This series of NATO Advanced Studies Institutes is intended to bridge the widening gap between basic immunobiology and its application to vaccination. There has been a rapid expansion of knowledge about subsets of lymphocytes and accessory cells, the chemistry of immunoglobulins, cytokines, adhesion molecules and the complex interactions required for cellular and humoral responses to antigenic stimulation. A great deal of information has accumulated about the structure of bacterial, viral and other antigens. Many of these can be produced by recombinant DNA technology or peptide synthesis. Yet the practice of vaccination has changed very little during the past decade. New live virus vaccines have been introduced, including attenuated varicella-zoster virus (Oka strain of VZV, Takahashi, 1990). However, this strain, and other live viruses, can produce severe infections in immunocompromized recipients (Gershon et al., 1984). It is now recognized that immunodeficiency is commoner than formerly believed, for nutritional and other reasons (Chandra, 1991). Hence live viruses and bacteria, including vectors of antigens, may have undesirable effects in some recipients, and emphasis is now placed on optimizing the efficiency of subunit vaccines.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Allison, A.C. and Byars, N.E., 1986, An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and cell-mediated immunity, J.Immun. Methods, 95:157
Allison, A.C. and Byars, N.E., 1992, Adjuvants for a new generation of vaccines, Can. J. Infect.Dis., 3:84B
Allison, A.C. and Davies, A.J.S., 1971, Requirement of thymus-dependent lymphocytes for potentiation by adjuvants of antibody formation, Nature, 233:330
Allison, A.C. and Gregoriadis, G., 1974, Liposomes as immunological adjuvants, Nature, 252:252
Arden, N.H., Patricarca, P.A. and Kendal, A.P., 1986, jn: “Options for Controls of Influenza”, P.A. Kendal and P.A. Patricarca, eds., Alan R. Liss, New York
Ambrose, M.W., Wyde, P.R. and Ewasishyn, M., 1993, Evaluation of the immunogenicity and protective efficacy of a candidate parainfluenza virus type 3 subunit vaccine in cotton rats, Vaccine, 9:505
Alper, C.A., Krushall, M.S. and Marcus-Bagley, D., 1989, Genetic predictions of nonresponse to hepatitis B vaccine, N.Engl.J.Med., 321:708
Audibert, F.M. and Lise, L.D, 1993, Adjuvants: current status, clinical perspectives and future prospects, Immunol. Today, 14:281
Beasley, R.P. and Hwang, L.Y. 1984, Hepatocellular carcinoma and hepatitis B virus, Semin. Liver Dis., 4:113
Beasley, R.P., Hwang, L.Y., Lee, G.C., 1983, Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immunoglobulin and hepatitis B vaccine, Lancet, ii:1099
Belshe, B.B., Van Wors, L.P. and Mufson, M.A., 1982, Parenteral administration of a live respiratory syncytial virus vaccine: results of a field trial, J.Inf.Dis., 145: 311
Bomford, R. 1989. Aluminium salts: perspectives on their use as adjuvants, in: “Immunological Adjuvants & Vaccines”, NATO ASI Series, Gregoriadis, G., Allison, A.C., Poste, G., eds., Plenum Press, London
Burt, D.S., Warren, A.P. and Barnett, B.C., 1993, Antigenic variation and the T-lymphocyte repertoire for influenza hemagglutinin, in: “Viruses and the Cellular Immune Response”, D.B. Thomas, ed., Marcel Dekker, New York
Byars, N.E., Allison, A.C., Harman, M.W. and Kendall, A.P., 1990, Enhancement of antibody responses to influenza B hemagglutinin by the use of a new adjuvant formulation, Vaccine8:49
Byars, N.E., Fraser-Smith, E.B., Pecyk, R.A., 1994, Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection, Vaccine, 12:200
Byars, N.E., Nakano, G., Welch, M., 1991, Improvement of hepatitis B vaccine by the use of a new adjuvant, Vaccine, 9:308
Campbell, M.J. Esserman, L., Byars, N.E., Allison, A.C. and Levy, R., 1989, Development of a new therapeutic approach to B-cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor, Intern.Rev.Immunol., 4:251
Chandra, R.K., 1991, Nutrition and immunity, in: “Clinical Immunology”, J. Brostoff, G.K. Scadding, D.K. Mole, I.M. Boitt, eds., Lipincoatt, Philadelphia
Chedid, L., Parant, M.A., Audibert, F. et al.1982, Biological activity of a new synthetic muramyl peptide devoid of pyrogenicity, Infect.Immun., 35:417
Choo, Q.L., Kuo, E., Weiner, A.J. et al.1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome, Science, 244:359
Clarke, B.E., Braun, A.L., Grace, K.G. et al. 1990, Presentation and immunogenicity of viral epitopes on the surface of hybrid hepatitis B virus core particles produced in bacteria, J.Gen.Virol., 71:1109
Dresser, D.W. and Mitchison, N.A., 1968, The mechanism of immunological paralysis, in: “Advances in Immunology”, Vol. 8, F.J. Dixon, Jr., H.G. Kunkel, eds., Academic Press, New York
Ellouz, F., Adam, A., Ciorbaru, R. and Lederer, E., 1974, Minimal structural requirements for adjuvant activity of bacterial peptidoglycans, Biochem.Biophys.Res.Comm., 59:1317
Epstein, M.A., Achong, B.G., eds., 1979, in. “The Epstein-Barr Virus”, Springer-Verlag, Berlin
Finkelman, F.D., Holmes, J., Katona, I.M., et al. 1990, Lymphokine control of in vivoimmunoglobulin isotype selection, Ann.Rev.Immunol., 8:303
Francis, M.J., Hastings, G.Z., Braun, F. et al., 1991, Immunological evaluation of the multiple antigen peptide (MAP) system using the major immunogenic site of foot- and-mouth disease virus, Immunology, 73:249
Freund, J., 1951, The effect of paraffin oil and mycobacteria on antibody formation and sensitization, Am.J.Clin.Pathol., 21:645
Gershon, A.A., Steinberg, S.P., Gelle, L. et al.1984, Live varicella vaccine: efficacy for children with leukemia in remission, JAMA, 252:355
Gilmour, J.E., Senior, J.M., Burns, N.E. et al.1989, A novel method for purification of HIV-1 p24 protein from hybrid Ty virus-like particles. (Ty-VLPS), AIDS, 3:717
Hamaoka, T., Katz, D.H., Benacerraf, B. 1973. Hapten-specific antibody responses in mice II. Cooperative interactions between adoptively transferred T- and B-lymphocytes in the development of IgE response, J.Exp.Med., 138:538
Hayward, A.J., Giller, R. and Levin, M., 1989, Phenotype, cytotoxic and helper functions of T-cells from varicella-zoster virus stimulated cultures of human lymphocytes, Virol. Immunol., 2:175
Holt, L.B., 1949, Quantitative studies in diphtheria prophylaxis: the primary response, BnL Exp.Pathol.30:289.
Imoto, M., Yoshimura, H., Sakaguchi, N., Kusumoto, S. and Shiba, T., 1987, Total synthesis of Escherichia colilipid A, Tetrahedron Lett., 26:1545
Kaminski, M.S., Kitamura, K. Maloney, D.G., et al1986, Importance of antibody isotype in monoclonal anti-idiotype therapy of murine B-cell lymphoma. A study of hybridoma class-switch variants, J.Immunol., 136:1123
Kenney, J.S., Hughes, B.M. and Allison, A.C., 1990, Determination of antibody affinity and concentration by solution-phase microradioimmunoassay, in: “Laboratory Methods in Immunology”, H. Zola, ed., CRC Press, Boca Raton
Kenney, J.S., Hughes, B.W., Masada, M.P. and Allison, A.C., 1989, Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies, J.Immunol. Methods, 121:157
Kayhty, H., Eskola, J., Pettola, H. et al.1991. Antibody responses to four Haemophilus influenzaetype 6 conjugate vaccines, Amer.J.Dis.Child., 145:223
Kit, S. and Kit, M., 1991, Genetically engineered herpesvirus vaccines. Accomplishments in pigs and prospects in humans, Progr. Med. Virol., 38:128
Klaus, G.G., Humphrey, J.H., Kunkl, A. and Dongworth, D.W., 1980, The follicular dendritic cell: Its role in antigen presentation and in the generation of immunological memory, Immunol.Rev., 53:3
Knight, S.C., Macatonia, S.E., Roberts, M.S. et al.1993. Dendritic cells and antigen presentation, in: “Viruses and the Cellular Immune Response”, D.B. Thomas, ed., Marcel Dekker, New York
Kwak, L.W., Campbell, M.J., Czerwinkski, D.K. et al. 1992, Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors, N.Engl.Med., 327:1209
Lifely, M.R., 1993, Polysaccharide vaccines, in: “New Generation Vaccines”, G. Gregoriadis, A.C. Allison, G. Poste, eds., Plenum Press, New York
McKay, P., Lees, J., and Murray, K., 1981, The conversion of hepatitis B core antigen synthesized in E. coliinto E antigen, J.Med.Virol., 8:237
McKercher, P.D., 1986, Oil adjuvants: their use in veterinary biologies, in: “Advances in Carriers and Adjuvants for Veterinary Biologies”, R.M. Nervig, P. Gough, M.L. Kaeberle, eds., Iowa State University Press, Ames, Iowa
Milich, D.R. and Chisari, F.V., 1982., Genetic restriction of the immune response to hepatitis B surface antigen (HBsAg). I. Restriction of the murine humoral response to the a and d determinants of HBsAg, J.Immunol., 129:320
Morgan, A.J., Allison, A.C., Finerty, S. et al.1989, Validation of a first generation Epstein-Barr virus vaccine preparation suitable for human use, J.Med.ViroL, 29:74
Morris, A.G., Lin, Y.-L. and Askonas, B.A., 1982, Immune interferon release when a cloned cytotoxic T-cell line meets its correct influenza-infected target, Nature, 95:150
Murray, J.L., Kleinerman, E.S., Cunningham, J.E. et al. 1989, Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients, J.Clin.Oncol., 7:1915
Murray, K., Bruce, S.A., Hinnen, P. et al.1984, Hepatitis B virus antigens made in microbial cells immunize against viral infection, EMBO J., 3:645
Murray, R., Cohen, P. and Hardegree, M.C., 1972, Mineral oil adjuvants: biological and chemical studies, Ann.Allerg., 30:146
Okazaki, W., Purchase, H.G. and Burmester, P.R., 1970, Protection against Marek’s disease by vaccination with a herpesvirus of turkeys, Avian Pis., 14:213
Persson, G.R., Engel, P., Whitney, C. et al. 1994, Immunization against Porphyromonas gingivalisinhibits progression of experimental periodontitis in nonhuman primates, Infect.Immun., 62:1026
Reichmann, L., Clark, M., Waldmann, H. and Winter, G., 1988, Reshaping human antibodies for therapy, Nature, 332:323
Ribi, E., Ulrich, J.T. and Masihi, K.N., 1993, Immunopotentiating activities of monophosphoryl lipid A, in: “Immunopharmacology of Infectious Piseases: Vaccine Adjuvants and Modulation of Non-specific Resistance”, J.A. Majde, ed., Alan R. Liss, New York
Ron, Y. and Sprent, J., 1987, T-cell priming in vitro: A major role for B-cells in presenting antigen to T-cells in lymph nodes, J.ImmunoL, 138:2848.
Rossmann, M.G., Arnold, E., Erickson, J.W. et al.1985, Structure of a human common cold virus and functional relationship to other picornaviruses, Nature, 317:145
Scheuermann, R.H., Racila, E., Tucker, T. et al.1994, Lintyrosine kinase signals cell cycle arrest but not apoptosis in B-lineage lymphoma cells, Proc.Natl.Acad.Sci.USA, 91:4098
Scolnick, E.M., McLean, A.A., West, P.J. et al. 1984, Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant PNA, JAMA, 251:2812
Spitznagel, J.K. and Allison, A.C., 1970, Mode of action of adjuvants: effects on antibody responses to macrophage-associated bovine serum albumin, J.Immunol., 104:128
Steinman, R.M ., 1991, The dendritic cell system and its role in immunogenicity, Ann.Rev. Immunol., 7:91.
Szakal, A.K., Kosco, M.H. and Tew, J.G., 1989, Microanatomy of lymphoid tissue during humoral immune responses: Structure function relationships, Ann.Rev.Immunol., 7:91
Takahashi, H., Takeshita, T., Morein, B. et al.1990, Induction of CP8+ cytotoxic T-cells by immunization with purified HIV-1 envelope protein in ISCOMS, Nature, 344:873
Tam, J.P., 1988, Synthetic peptide vaccine design: synthesis and properties of a high density multiple peptide antigenic system, Proc.Natl.Acad.Sci.USA, 85:5409
Thomas, D.B., Burt, D.S., Barnett, B.C. et al. 1989, B- and T-cell recognition of influenza virus hemagglutinin, Cold Spr. Harbor Symp.Quant.Biol., 54:487
Tsujimoto, M., Kinoshita, F., Okunaga, T., Kotani, T., Kusumoto, S., Yamamoto, K. and Shiba, T., 1979, Higher immunoadjuvant activities of N-acetyl-p-P-glucosaminyl-(l- 4)-N-aeetylmuramyl-L-alanyl-P-iso glutamine in comparison with N- acetamylmuramyl-L-alanyl-P-isoglytamine, Microbiol.Immunol., 23:933
Unanue, E.R., Askonas, B.A. and Allison, A.C., 1969, A role of macrophages in the stimulation of immune responses by adjuvants, J.Immunol., 103:71
Unkeless, J.C., Scigliano, E. and Freedman, V.H., 1988, Structure and function of human and murine receptors for IgG, Ann.Rev.Immunol., 6:251
Valenzuela, P., Medina, A., Rutter, W.J. et al.1982, Synthesis and assembly of hepatitis B virus surface antigen in yeast, Nature, 298:347
Van Regenmortel, M.H.V., 1990, Structure of viral B-cell epitopes, Res.Microbiol., 141:747
Van Rooijen, N . 1992. Macrophages as accessory cells in the in vivo humoral immune response: from processing of particulate antigens to regulation by suppression, Seniin. Immunol., 4:237
Vijay, H.M., Lavregne, G., Huang, H. and Bernstein, I.L., 1979, Preferential synthesis of IgE reaginic antibodies in rats immunized with alum adsorbed antigens, Int.Arch.Allergy Appl.Immunol., 59:227
Virelizier, J.L., Allison, A.C. and Schild, J.S., 1979, Immune response to influenza virus in the mouse, Brit. Med. Bull., 35:65
Vitetta, E.S. and Uhr, J.W. 1994, Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy, Cancer Res, in press
Walker, B.D., Flexner, C., Paradis, T.J. et al.1988, HIV-1 reverse transcriptase is a target for cytotoxic T-lymphocytes in infected individuals, Science, 240:64
Walker, M.E., Smuzness, W., Stevens, C. et al.1981, Genetics of anti-HBs responsiveness. HLA-DR7 and nonresponsiveness to hepatitis vaccinations, Proc.Am.Assoc.Blood Banks, 321:708
Waters, R.V., Terrell, T.G. and Jones, G.H., 1982, Uveitis induction in the rabbit by muramyl dipeptides, Infect.Immun., 51:816
White, R.G. 1976, The adjuvant effect of microbial products on the immune response, Ann.Rev.Microbial., 30:579
Wilson, I.A. and Cox, N.J., 1990, Structural basis of immune recognition of influenza virus hemmagglutinin, Annu.Rev.Immunol., 8:737
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Plenum Press, New York
About this chapter
Cite this chapter
Allison, A.C. (1995). Adjuvants for New and Improved Vaccines. In: Gregoriadis, G., McCormack, B., Allison, A.C. (eds) Vaccines. Nato Science Series, vol 282. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0357-2_1
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0357-2_1
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-8014-6
Online ISBN: 978-1-4613-0357-2
eBook Packages: Springer Book Archive